View More Recent Stories

Dec 19, 2017 05:38PM Biogen (BIIB) and Ionis (IONS) Enter Agreement to Identify Novel Therapies for Treatment of SMA
Dec 19, 2017 04:06PM Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
Nov 1, 2017 05:07PM Biogen (BIIB), Ionis (IONS) Announces NEJM Publishes First Phase 3 Study Results of SPINRAZA for Treatment of Spinal Muscular Atrophy
Nov 1, 2017 05:06PM The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
Oct 5, 2017 07:32AM Biogen (BIIB) Reports SPINRAZA (Nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function
Oct 5, 2017 07:30AM Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
Jun 29, 2017 07:33AM Biogen (BIIB) Says New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA in SMA
Jun 29, 2017 07:30AM New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
Jun 1, 2017 07:31AM Biogen (BIIB) Says SPINRAZA Approved in EU as First Treatment for Spinal Muscular Atrophy
Jun 1, 2017 07:30AM SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy
Apr 24, 2017 07:32AM Biogen (BIIB) Says Final Phase 3 Study Data Show SPINRAZA Significantly Improved Motor Function in Children with Later-Onset SMA
Apr 24, 2017 07:30AM Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Apr 21, 2017 02:02PM Biogen (BIIB) Report Positive CHMP Opinion on SPINRAZA for Treatment of Spinal Muscular Atrophy
Apr 21, 2017 02:00PM Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Jan 13, 2017 07:33AM Biogen (BIIB) Phase 3 Data on SPINRAZA Shows Significantly Reduced Risk of Death in SMA
Jan 13, 2017 07:30AM New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Dec 27, 2016 05:45AM Biogen (BIIB) Receives FDA Approval for SPINRAZA to Treat SMA (IONS)
Dec 23, 2016 05:08PM U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
Dec 23, 2016 04:51PM U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
Nov 7, 2016 07:32AM Biogen (BIIB), Ionis Pharma (IONS) Announce SPINRAZA Phase 3 Met Primary Endpoint in Later-Onset SMA
Nov 7, 2016 07:30AM Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
Oct 28, 2016 07:38AM Biogen (BIIB) Announces U.S. FDA, EMA Acceptance of Nusinersen Regulatory Applications
Oct 28, 2016 07:30AM Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Oct 8, 2016 10:00AM New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy
Oct 6, 2016 09:22AM Pre-Open Stock Movers 10/06: (ALQA) (SCYX) (ZUMZ) Higher; (ALNY) (TWTR) (MDCO) Lower (more...)
Sep 26, 2016 07:52AM Biogen (BIIB), Ionis (IONS) Announce Completion of Nusinersen NDA Rolling Submission as SMA Treatment
Sep 26, 2016 07:30AM Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
Aug 1, 2016 07:34AM Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA
Aug 1, 2016 07:30AM Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
View More Recent Stories